When was TC Biopharm founded?

TC Biopharm was founded in 2013.

Where is TC Biopharm located?

TC Biopharm is located in Edinburgh, United Kingdom .

How many employees does TC Biopharm have?

TC Biopharm has 79 employees as of Dec 31, 2020.

When was the latest funding round of TC Biopharm?

TC Biopharm's latest funding round was on Nov 28, 2022.

What is the annual revenue of TC Biopharm?

Annual revenue of TC Biopharm is 拢1.98惭 as on Dec 31, 2018.

Where does TC Biopharm rank among its competitors?

TC Biopharm ranks 670 amongst 3147 active competitors.

Who are the top competitors of TC Biopharm?

TC Biopharm's top competitors are Moderna, Jazz Pharmaceuticals and BeiGene.

TC Biopharm - 2025 Company Profile, Team, Funding, Competitors & Financials

TC Biopharm is a public company based in Edinburgh (United Kingdom), founded in 2013 by . It operates as a Developer of T-cell therapies for cancer and infectious disease treatment. TC Biopharm has raised $10.6M in funding. The company has 3147 active competitors, including 1071 funded and 740 that have exited. Its top competitors include companies like Moderna, Jazz Pharmaceuticals and BeiGene.

Company Details

Developer of T-cell therapies for cancer and infectious disease treatment. The company is developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

Website
Social

Key Metrics

Founded Year

2013

Location

Edinburgh, United Kingdom

Stage

Public

Total Funding

in 8 rounds

Latest Funding Round

Investors

& 8 more

Ranked

670^th among

Annual Revenue

as on Dec 31, 2018

Employee Count

as on Dec 31, 2020

Similar Companies

Jazz Pharmaceuticals &

Exit Details

Public

TC Biopharm is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CIN: 1872812 United States, Active		$1 - $1M (as on Dec 13, 2022)	-	-
TC BIOPHARM LIMITED CIN: SC453579 United Kingdom, Active	Jun 30, 2013	$4.69M (as on Dec 31, 2018)	79 (as on Dec 31, 2020)

Get your free copy of TC Biopharm's company profile

TC Biopharm has raised a total funding of $10.6M over 8 rounds. Its first funding round was on Mar 11, 2014.

TC Biopharm has 9 institutional investors including , EIC Fund and .

Here is the list of recent funding rounds of TC Biopharm:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Nov 28, 2022	$7.35M	Post IPO	8747538	2391267	-
Sep 30, 2019	$4.33M	Grant (prize money)	8750141	4760480	EIC Fund
Oct 01, 2017	$4.31M	Grant (prize money)	8052331	1916557

Access funding benchmarks and valuations. Sign up today!

View details of TC Biopharm's funding rounds and investors

The founders of TC Biopharm is .

Here are the details of TC Biopharm's key team members:

: CoFounder of TC Biopharm. They are also an angel investor in .
Contact Info:

View details of

TC Biopharm's employee count trend

TC Biopharm has 79 employees as of Dec 20. The total employee count is 16.0% lower than what it was in Dec 19. Here is TC Biopharm's employee count trend over the years:

Uncover TC Biopharm's growth story! Sign up today!

Access 秘密研究所 on any website

Our Google Chrome extension lets you view company details while browsing their websites

Top competitors of TC Biopharm include Moderna, Jazz Pharmaceuticals and BeiGene. Here is the list of Top 10 competitors of TC Biopharm, ranked by 秘密研究所 score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	BB Biotech, Gershon Capital听&补尘辫;听	80/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Oak Hill, InterWest Partners听&补尘辫;听	80/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Rock Springs Capital, T. Rowe Price听&补尘辫;听	78/100
4th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	HBM Partners, Vivo Capital听&补尘辫;听	77/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer.	$317M	Ridgeback Capital Management, BB Biotech听&补尘辫;听	73/100
6th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for treating cancer	$181M	BB Biotech, Colt Ventures听&补尘辫;听	72/100
7th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	Tekla Capital Management, Ridgeback Capital Management听&补尘辫;听	71/100
8th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Ridgeback Capital Management, Roche听&补尘辫;听	71/100
9th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	BB Biotech, Avoro Capital Advisors听&补尘辫;听	71/100
10th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Aisling Capital, Avoro Capital Advisors听&补尘辫;听	71/100
670th	2013, Edinburgh (United Kingdom), Public	Developer of T-cell therapies for cancer and infectious disease treatment	$10.6M	, EIC Fund听&补尘辫;听	44/100